Cenobamat w leczeniu epilepsji związanej z guzami mózgu: doświadczenia z wielu ośrodków medycznych
PubMedEpilepsia Open
Cenobamate in brain tumor-related epilepsy: A multicenter real-world experience
W skrócie
Badanie sprawdzało skuteczność nowego leku przeciwpadaczkowego zwanego cenobamatem u 20 pacjentów z trudną do kontrolowania epilepsją spowodowaną guzami mózgu. Po roku leczenia pacjenci mieli znacznie mniej napadów padaczkowych (zmniejszenie o ponad 80%), a u czterech osób udało się całkowicie zatrzymać napady, chociaż u części pacjentów pojawiły się działania niepożądane, głównie senność. Wyniki sugerują, że cenobamat może być pomocny u niektórych chorych na epilepsję związaną z guzami mózgu, ale potrzebne są większe badania, aby potwierdzić te obserwacje.
Oryginalny abstract (angielski)
OBJECTIVE: Cenobamate (CNB) is a novel antiseizure medication with a dual mechanism of action that has demonstrated high efficacy in drug-resistant focal epilepsy; however, evidence in brain tumor-related epilepsy (BTRE) remains limited. The study aimed to evaluate the effectiveness, safety, and tolerability of CNB as add-on therapy in a multicenter cohort of patients with BTRE. METHODS: We conducted a multicenter, retrospective observational study across tertiary epilepsy centers in the Lazio region, Italy. Adult patients with drug-resistant BTRE treated with CNB as adjunctive therapy were included. Seizure frequency was assessed at baseline and during follow-up. Primary outcomes were changes in monthly seizure frequency and responder rates. Effectiveness was analyzed in both the overall population and in a homogeneous cohort of patients with 6-month follow-up. RESULTS: Twenty patients (10 females, median age 48 years) were included. Tumor histology included meningioma (n = 7, 35%), astrocytoma (n = 4, 20%), glioblastoma (n = 3, 15%), ganglioglioma (n = 3, 15%), oligodendroglioma (n = 2, 10%), and dysembryoplastic neuroepithelial tumor (n = 1, 5%). In the overall analysis population (n = 20), after a median 12-month follow-up, median seizure frequency significantly decreased from 6 to 1 per month (p < 0.001), with a median reduction of 85.8% (IQR 51.4-96.7). Responder rates were 80% (≥50% seizure reduction), 60% (≥75%), and 20% achieved seizure freedom. Adverse events occurred in 12 patients (60%), including sedation (n = 8, 40%), postural instability (n = 3, 15%), diarrhea, and mild cutaneous rash (n = 1, 5% each). CNB was discontinued in one patient (5%). SIGNIFICANCE: In this multicenter real-world cohort of patients with drug-resistant BTRE and heterogeneous tumor histology, CNB was associated with a reduction in seizure frequency and was well tolerated. PLAIN LANGUAGE SUMMARY: Seizures caused by brain tumors can be difficult to control. We reviewed records from 20 adults who received cenobamate alongside their existing seizure medicines. At their last follow-up, 16 had at least half as many seizures, and four were seizure-free. Twelve patients experienced side effects, most commonly sleepiness; one stopped cenobamate because of a rash. These findings suggest that cenobamate may help some people with brain tumor-related epilepsy. However, the study was small, had no comparison group, and included patients with different tumors and follow-up durations. Larger studies are needed.
Metadane publikacji
Journal
Epilepsia Open
Data publikacji
16.11.2026
PMID
43037523
DOI
10.1002/epi4.70365
Autorzy
Romozzi M, Mazzeo A, Antonucci M, Assenza G, Bassetti MA, Fernandes M, Liguori C, Lippa G, Piccioli M, Pulitano P